Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 and Dianabol Interaction: Monitor | Peptide Database

Compound Profiles ACE-031 Myostatin Inhibitor | Experimental Muscle Growth ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Dianabol

Oral Anabolic Steroid | Classic Mass Builder

Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-alpha-alkylated structure allows it to survive first-pass hepatic metabolism, enabling oral bioavailability but placing significant stress on the liver.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take ACE-031 with Dianabol?

Yes, but with caution. Both ACE-031 and Dianabol suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and Dianabol safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, insulin disrupting, lipid disrupting. Monitor accordingly.

What are the interactions between ACE-031 and Dianabol?

Both ACE-031 and Dianabol suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and Dianabol?

ACE-031 has a half-life of 12-15 days and Dianabol has a half-life of ~4-6 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Myostatin and Cardiomyocyte Hypertrophy: Physiological vs Pathological Contexts

The distinction between physiological and pathological cardiac hypertrophy is mechanistically critical for interpreting ACE-031’s cardiac biology. Physiological hypertrophy (exercise-induce…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Clinical Trial Results and Development Status

ACE-031 entered Phase 1/2 clinical trials in boys with DMD. The trials demonstrated the expected pharmacological effects: serum myostatin suppression, rapid increases in total body lean mass (muscle), and reductions in fat mass within weeks of first dosing. The muscle mass accrual from ActRIIB blockade was confirmed in human DMD patients — demonstrating proof of mechanism. However, the trials were terminated by Acceleron due to safety findings: several subjects developed telangiectasias (small dilated blood vessels, particularly on the face and nose) and a small number experienced epistaxis (nosebleeds). These vascular findings were attributed to inhibition of activin A and other TGF-β family members in vascular endothelium — a consequence of ACE-031’s broader ActRIIB ligand capture beyond myostatin alone. The termination of ACE-031 development shifted focus toward more selective myostatin inhibitors (myostatin-specific antibodies such as domagrozumab, stamulumab, and later apitegromab for spinal muscular atrophy) that spare the activin A and GDF-11 signalling pathways responsible for the vascular adverse effects.

Source: peptideslabuk.com ↗

Can I use ACE-031 as a research chemical if I can find it?

ACE-031 has never been approved for human use and clinical development was discontinued. Any product sold as ACE-031 is of unknown origin and quality. The compound is a complex fusion protein sensitive to degradation, making DIY sourcing extremely risky with high contamination likelihood.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 (1 mg) Dosage Protocol

A soluble activin receptor type IIB (ActRIIB) Fc-fusion protein that traps myostatin and related muscle-limiting factors. Its clinical development was halted for safety. Research-use-only — this page is an educational reference and a caution, not a dosing recommendation.

Source: dosagepeptide.com ↗
Storage reference

Usage and Storage:

ACE-031 is supplied as a lyophilised solid to ensure maximum stability and ease of use in research environments. For best results, follow our website's detailed reconstitution and storage guidelines.

Source: uk-peptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides